Fortress Biotech, Inc.

Contributing Author

Recent Articles by Fortress Biotech, Inc.

Sep-08	Fortress Biotech to Present at the H.C. Wainwright 28th Annual Global Investment Conference FBIO GlobeNewswire
Aug-13	Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights FBIO +8.36% GlobeNewswire
Jul-27	Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $130 Million Series B Financing FBIO GlobeNewswire
May-18	Fortress Biotech to Participate in A.G.P.'s Annual Virtual Healthcare Conference FBIO GlobeNewswire
May-14	Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights FBIO GlobeNewswire
May-04	Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference FBIO GlobeNewswire
Mar-31	Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights FBIO FBIO -11.47% GlobeNewswire
Mar-30	Fortress Biotech's Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million FBIO GlobeNewswire
Feb-23	UPDATE: Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million FBIO GlobeNewswire
Feb-23	Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million FBIO GlobeNewswire
Jan-13	Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States FBIO -7.14% GlobeNewswire
Dec-15	Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission FBIO +13.31% GlobeNewswire
Nov-14	Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights FBIO +5.22% GlobeNewswire
Oct-21	Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics' Global Phase 3 Trials of Dotinurad for the Treatment of Gout FBIO GlobeNewswire
Oct-01	Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $205 Million Series A Financing FBIO -30.72% GlobeNewswire
Oct-01	Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101 FBIO -30.72% GlobeNewswire
Sep-02	Fortress Biotech to Present at the H.C. Wainwright 27th Annual Global Investment Conference FBIO +15.50% GlobeNewswire
Aug-14	Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights FBIO FBIO +8.16% GlobeNewswire
May-30	Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics FBIO GlobeNewswire
May-15	Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights FBIO +7.23% GlobeNewswire
May-07	Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference FBIO GlobeNewswire

Fortress Biotech, Inc.

Recent Articles by Fortress Biotech, Inc.

Upgrade your Finviz experience